Drug maker pleads guilty in drug fraud case
07/03/2012 // West Palm Beach, Florida, US // JusticeNewsFlash // Justice News Flash // (press release)
U.S. – Drug manufacturing giant GlaxoSmithKline (GSK) has agreed to plead guilty in a drug fraud case related to the marketing and sale of three of its well-known prescription drugs. As reported by CBC News, the multinational pharmaceutical company, which is headquartered in London, agreed to a settlement in which it will pay $3 billion in fines and enter a guilty plea for misdemeanor criminal and civil charges stemming from drug fraud claims.
As noted in the report, the company admitted to marketing antidepressants Paxil and Wellbutrin for unapproved uses and failing to provide safety information about diabetes drug Avandia regarding associated heart problem risks.
Deputy U.S. Attorney General James Cole is quoted in the report as stating in regards to the settlement, “At every level, we are determined to stop practices that jeopardize patients’ health; harm taxpayers; and violate the public trust — and this historic action is a clear warning to any company that chooses to break the law.”
The recent settlement is reportedly the largest related to health-care fraud in the history of the U.S.
Justice News Flash delivers the latest in U.S. product liability news.
Address: 215 South Olive Suite 300 W. Palm Beach FL 33401